What are the major opportunities in the Low-Grade Glioma market? What are the strategies for the Low-Grade Glioma market?

For detailed insights on the major opportunities and strategies in the Low-Grade Glioma market, Read More

How does the Low-Grade Glioma market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Low-Grade Glioma market growth and SWOT analysis of the Low-Grade Glioma industry, Read More

For detailed insights on the mergers and acquisitions in the Low-Grade Glioma industry,

What are the key dynamics influencing the Low-Grade Glioma market growth? SWOT analysis of the Low-Grade Glioma market. Read More

Global Low-Grade Glioma Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Low-Grade Glioma Global Market Report 2025

Name: Low-Grade Glioma Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Type (Trametinib, Dabrafenib, Ivosidenib, Mirdametinib), By Treatment (Surgery, Chemotherapy, Radiation), By Route Of Administration (Topical, Oral), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Low-Grade Glioma Market Overview

• Low-Grade Glioma market size has reached to $1.39 billion in 2024

• Expected to grow to $1.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%

• Growth Driver: Rising Incidence Of Brain Tumours Influences The Market Growth

• Market Trend: Advancements In Low-Grade Glioma Treatment

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

The main drug types of low-grade glioma are trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication used to treat certain types of cancer by inhibiting the MEK1/2 proteins involved in cancer cell growth. Low-grade glioma treatment generally includes a combination of surgery, chemotherapy, and radiation. Medications are delivered through various routes, including oral and topical administration, and are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Low-Grade Glioma Market Size and growth rate 2025 to 2029: Graph

What Is The Low-Grade Glioma Market Size 2025 And Growth Rate?

What Is The Low-Grade Glioma Market Growth Forecast?

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to a rising aging population, rising healthcare expenditure, increasing prevalence of brain tumors, growing government initiatives, and a rise in the incidence and prevalence of high-grade gliomas. Major trends in the forecast period include advancements in imaging technologies, development of radiation therapies, introduction of chemotherapy regimens, clinical trials expansion, and the integration of immunotherapy.

The forecast of 5.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neuro-oncology centers by driving up the cost of temozolomide and advanced MRI perfusion software sourced from Germany and Belgium, exacerbating brain tumor treatment costs and delaying precision medicine approaches. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Low-Grade Glioma Market Segmented?

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

What Is Driving The Low-Grade Glioma Market? Rising Incidence Of Brain Tumours Influences The Market Growth

The rising incidence of brain tumors is expected to propel the growth of the low-grade glioma market going forward. A brain tumor is an abnormal growth of cells in the brain or surrounding areas, which can be benign or malignant. The rising incidence of brain tumors is due to factors such as increased exposure to radiation, environmental pollutants, genetic predisposition, and aging. Low-grade glioma is helpful for brain tumors by utilizing advanced diagnostic techniques and targeted therapies such as surgery, radiation, and chemotherapy, which help slow tumor progression, preserve neurological function, and improve patient outcomes, making early detection and personalized treatment crucial for managing other brain tumors with similar growth patterns. For instance, in October 2023, according to The Central Brain Tumor Registry of the United States (CBTRUS), a US-based not-for-profit organization, in 2022, the worldwide incidence of primary malignant brain tumors was approximately 3.5 per 100,000, with higher rates in high-income countries (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. Therefore, the rising incidence of brain tumors is driving the growth of the low-grade glioma industry.

Who Are The Major Players In The Global Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

What Are The Key Trends Of The Global Low-Grade Glioma Market? Advancements In Low-Grade Glioma Treatment

Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted therapy, such as genetic alteration drugs, to gain a competitive edge and enhance the treatment of children with low-grade glioma. Genetic alteration drugs are targeted therapies designed to modify or inhibit specific genetic mutations or abnormalities in cells, helping to treat diseases such as cancer by blocking the pathways that drive uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients with limited prior treatment options.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Low-Grade Glioma Market? Ipsen And Day One Biopharmaceuticals Partner To Commercialize Tovorafenib For Pediatric Brain Tumour

In July 2024, Ipsen Biopharmaceuticals Inc., a US-based pharmaceutical company, collaborated with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for pediatric low-grade glioma (pLGG) with BRAF mutations. This collaboration aims to expand global access to the treatment while leveraging Ipsen’s oncology expertise and international reach to accelerate regulatory and commercial efforts outside the US. Day One Biopharmaceuticals is a US-based clinical-stage biopharmaceutical company that is primarily focused on developing targeted therapies for pediatric low-grade glioma.

What Is The Regional Outlook For The Global Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Low-Grade Glioma Market?

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Low-Grade Glioma Industry?

The low-grade glioma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the low-grade glioma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

LowGrade Glioma Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.47 billion
Revenue Forecast In 2034	$1.84 billion
Growth Rate	CAGR of 5.7% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The low-grade glioma market covered in this report is segmented – 1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib 2) By Treatment: Surgery, Chemotherapy, Radiation 3) By Route Of Administration: Topical, Oral 4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Low-Grade Glioma Market Characteristics

3. Low-Grade Glioma Market Trends And Strategies

4. Low-Grade Glioma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Low-Grade Glioma Growth Analysis And Strategic Analysis Framework

5.1. Global Low-Grade Glioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Low-Grade Glioma Market Growth Rate Analysis

5.4. Global Low-Grade Glioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Low-Grade Glioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Low-Grade Glioma Total Addressable Market (TAM)

6. Low-Grade Glioma Market Segmentation

6.1. Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Trametinib

Dabrafenib

Ivosidenib

Mirdametinib

6.2. Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Surgery

Chemotherapy

Radiation

6.3. Global Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Topical

Oral

6.4. Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

7. Low-Grade Glioma Market Regional And Country Analysis

7.1. Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Low-Grade Glioma Market

8.1. Asia-Pacific Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Low-Grade Glioma Market

9.1. China Low-Grade Glioma Market Overview

9.2. China Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Low-Grade Glioma Market

10.1. India Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Low-Grade Glioma Market

11.1. Japan Low-Grade Glioma Market Overview

11.2. Japan Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Low-Grade Glioma Market

12.1. Australia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Low-Grade Glioma Market

13.1. Indonesia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Low-Grade Glioma Market

14.1. South Korea Low-Grade Glioma Market Overview

14.2. South Korea Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Low-Grade Glioma Market

15.1. Western Europe Low-Grade Glioma Market Overview

15.2. Western Europe Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Low-Grade Glioma Market

16.1. UK Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Low-Grade Glioma Market

17.1. Germany Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Low-Grade Glioma Market

18.1. France Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Low-Grade Glioma Market

19.1. Italy Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Low-Grade Glioma Market

20.1. Spain Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Low-Grade Glioma Market

21.1. Eastern Europe Low-Grade Glioma Market Overview

21.2. Eastern Europe Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Low-Grade Glioma Market

22.1. Russia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Low-Grade Glioma Market

23.1. North America Low-Grade Glioma Market Overview

23.2. North America Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Low-Grade Glioma Market

24.1. USA Low-Grade Glioma Market Overview

24.2. USA Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Low-Grade Glioma Market

25.1. Canada Low-Grade Glioma Market Overview

25.2. Canada Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Low-Grade Glioma Market

26.1. South America Low-Grade Glioma Market Overview

26.2. South America Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Low-Grade Glioma Market

27.1. Brazil Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Low-Grade Glioma Market

28.1. Middle East Low-Grade Glioma Market Overview

28.2. Middle East Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Low-Grade Glioma Market

29.1. Africa Low-Grade Glioma Market Overview

29.2. Africa Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Low-Grade Glioma Market Competitive Landscape And Company Profiles

30.1. Low-Grade Glioma Market Competitive Landscape

30.2. Low-Grade Glioma Market Company Profiles

30.2.1. McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Low-Grade Glioma Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Daiichi Sankyo Company Limited

31.3. Ipsen S.A.

31.4. BeiGene Ltd.

31.5. NovoCure Limited

31.6. Les Laboratoires Servier

31.7. Day One Biopharmaceuticals Inc.

31.8. CStone Pharmaceuticals Co. Ltd.

31.9. AnHeart Therapeutics Inc.

31.10. Apollomics Inc.

31.11. Agios Pharmaceuticals Inc.

31.12. BioMed Valley Discoveries Inc.

31.13. Avistone Biotechnology Co. Ltd.

31.14. NextSource Biotechnology LLC

31.15. Sunesis Pharmaceuticals Inc.

32. Global Low-Grade Glioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Low-Grade Glioma Market

34. Recent Developments In The Low-Grade Glioma Market

35. Low-Grade Glioma Market High Potential Countries, Segments and Strategies

35.1 Low-Grade Glioma Market In 2029 - Countries Offering Most New Opportunities

35.2 Low-Grade Glioma Market In 2029 - Segments Offering Most New Opportunities

35.3 Low-Grade Glioma Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: China, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: India, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: Japan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Australia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Indonesia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Indonesia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: South Korea, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: South Korea, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Western Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Western Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: UK, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: UK, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Germany, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Germany, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: France, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: France, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Italy, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Italy, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Spain, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Spain, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Eastern Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Eastern Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Russia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Russia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: North America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: North America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: USA, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: USA, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: Canada, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Canada, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: South America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: South America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Brazil, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Brazil, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Middle East, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Middle East, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Africa, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Africa, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: McKesson Corporation Financial Performance

Table 76: F. Hoffmann-La Roche Ltd Financial Performance

Table 77: Merck & Co. Inc. Financial Performance

Table 78: Bristol-Myers Squibb Company Financial Performance

Table 79: AstraZeneca PLC Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: China, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: India, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: Japan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Australia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Indonesia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Indonesia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: South Korea, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: South Korea, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Western Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Western Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: UK, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: UK, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Germany, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Germany, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: France, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: France, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Italy, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Italy, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Spain, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Spain, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Eastern Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Eastern Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Russia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Russia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: North America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: North America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: USA, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: USA, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: Canada, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Canada, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: South America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: South America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Brazil, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Brazil, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Middle East, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Middle East, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Africa, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Africa, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: McKesson Corporation Financial Performance

Figure 76: F. Hoffmann-La Roche Ltd Financial Performance

Figure 77: Merck & Co. Inc. Financial Performance

Figure 78: Bristol-Myers Squibb Company Financial Performance

Figure 79: AstraZeneca PLC Financial Performance

Emerging Trends and Growth Drivers in the Pediatric Dental Market Through 2029

Competitive and Market Trend Analysis of Pharmaceutical Cold Chain Packaging Industry Through 2029

Key Market Drivers, Trends, and Forecast for the Global Pharmaceutical Warehousing Industry

2025 Analysis: Opportunities and Risks in the Evolving Precision Genomic Testing Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Adult Malignant Glioma Therapeutics Global Market Report 2025 – By Type Of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types), By Therapy (Ch...

Glioblastoma Multiforme Global Market Report 2025 – By Drug Class (Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes), By Diagnostic Tools (Magnetic Resonance Imaging (MRI), Computed Tomography...

Pontine Glioma Drugs Global Market Report 2025 – By Type (Diffuse Brain Stem Glioma, Focal Brain Stem Glioma, Recurrent Brain Stem Glioma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application (Ca...

Acoustic Neuroma Global Market Report 2025 – By Type (Unilateral Vestibular Schwannomas, Bilateral Vestibular Schwannomas), By Treatment Type (Drugs, Anticonvulsants, Radiation Therapy, Proton Therapy, Stereotactic Radio...

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 – By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drug Class (Temozolomid...

Paraganglioma Global Market Report 2025 – By Type (Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Pa...

Brain Tumor Drugs Global Market Report 2025 – By Drugs (Temozolomide, Bevacizumab, Other Drugs), By End User (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users) – Impact of Tariff and Trade War on Marke...

Frequently Asked Questions

What is the definition of the Low-Grade Glioma market?

How will the Low-Grade Glioma market drivers and restraints affect the market dynamics? What forces will shape the Low-Grade Glioma industry going forward?

The market major growth driver - Rising Incidence Of Brain Tumours Influences The Market Growth. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Low-Grade Glioma market?

The low-grade glioma market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.47 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to growth in awareness of brain tumors, increased funding in oncology spurred research, an increase in orphan drug designations, the expansion of telemedicine, and an increase in healthcare access. The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to " $1.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to a rising aging population, rising healthcare expenditure, increasing prevalence of brain tumors, growing government initiatives, and a rise in the incidence and prevalence of high-grade gliomas. Major trends in the forecast period include advancements in imaging technologies, development of radiation therapies, introduction of chemotherapy regimens, clinical trials expansion, and the integration of immunotherapy. For further insights on this market, request a sample here

How is the Low-Grade Glioma market segmented?

The low-grade gliomamarket covered in this report is segmented –
1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib
2) By Treatment: Surgery; Chemotherapy; Radiation
3) By Route Of Administration: Topical; Oral
4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies For further insights on this market, request a sample here

Which region has the largest share of the Low-Grade Glioma market? What are the other regions covered in the report?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Low-Grade Glioma market?

What are the key trends in the Low-Grade Glioma market?

Major trends in this market include Advancements In Low-Grade Glioma Treatment. For further insights on this market, request a sample here.